Y Intercept Hong Kong Ltd Takes Position in Zura Bio Limited $ZURA

Y Intercept Hong Kong Ltd purchased a new position in Zura Bio Limited (NASDAQ:ZURA) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 107,881 shares of the company’s stock, valued at approximately $113,000.

A number of other institutional investors also recently added to or reduced their stakes in ZURA. Bank of America Corp DE raised its holdings in Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares in the last quarter. Nuveen LLC bought a new stake in shares of Zura Bio in the 1st quarter valued at about $76,000. Forefront Analytics LLC grew its position in shares of Zura Bio by 101.6% in the 1st quarter. Forefront Analytics LLC now owns 108,308 shares of the company’s stock worth $140,000 after buying an additional 54,574 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Zura Bio by 2.4% during the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock worth $1,981,000 after acquiring an additional 36,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC raised its stake in shares of Zura Bio by 34.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock worth $3,614,000 after acquiring an additional 723,933 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

Shares of ZURA opened at $3.67 on Monday. The company’s fifty day moving average price is $3.08 and its 200-day moving average price is $1.97. Zura Bio Limited has a 1-year low of $0.97 and a 1-year high of $4.85. The firm has a market capitalization of $238.62 million, a PE ratio of -5.24 and a beta of 0.24.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. As a group, research analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZURA. Oppenheimer lowered their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, August 15th. HC Wainwright lowered their price objective on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. Wall Street Zen raised Zura Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Zura Bio in a report on Tuesday, September 30th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.75.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.